

e-ISSN: 2621 - 4814

# Borneo Journal of ..... **PHARMACY**

Volume 7 Issue 1 February 2024

*Accredited at SINTA 2 until February 2025  
by Ministry of Research and Technology / National Research and Innovation Agency, Indonesia  
No: 148/M/KPT/2020.*



**Institute for Research and Community Services**  
Universitas Muhammadiyah Palangkaraya

# BORNEO JOURNAL OF PHARMACY

Borneo J Pharm  
e-ISSN: 2621-4814

Volume 7 Issue 1 February 2024

Department of Pharmacy  
Faculty of Health Sciences  
Universitas Muhammadiyah Palangkaraya

## EDITOR IN CHIEF

**Mohammad Rizki Fadhil Pratama**

Universitas Muhammadiyah Palangkaraya, Indonesia  
ORCID: <https://orcid.org/0000-0002-0727-4392>

## MANAGING EDITOR

**Khalid Karrouchi**

Mohammed V University in Rabat, Morocco  
**Alaa Kareem Niamah**  
University of Basrah, Iraq  
**Neni Frimayanti**  
Sekolah Tinggi Ilmu Farmasi Riau, Indonesia  
**Erwin Martinez Fallar**  
San Pedro College, Philippines  
**Susi Novaryatiin**  
Universitas Muhammadiyah Palangkaraya,  
Indonesia

**Ahmed Mahal**  
Chinese Academy of Sciences, China  
**Lina Perekhoda**  
National University of Pharmacy, Ukraine  
**Jyoti Singh**  
CSIR-CIMAP, India  
**Shayma Thyab Gddoa Al-Sahlany**  
University of Basrah, Iraq

**Quazi Majaz Ahamed Aejazuddin**  
Ali Allana College of Pharmacy, India  
**Nalini Kanta Sahoo**  
Marri Laxman Reddy Institute of Pharmacy, India  
**Luis Castillo Henriquez**  
Universidad de Costa Rica, Costa Rica  
**Heng Yen Khong**  
Universiti Teknologi MARA Sarawak, Malaysia  
**Syahrida Dian Ardhany**  
Universitas Muhammadiyah Palangkaraya,  
Indonesia

## REVIEWER

**Keni Vidilaseris**  
University of Helsinki, Finland  
**Oleh M Koshovyi**  
National University of Pharmacy, Ukraine  
**Atul Kabra**  
Raffles University, India  
**Arthi Venkatesan**  
ALTEM Technologies, India  
**Ashraf Ahmed Ali Abdusalam**  
Sirte University, Libya  
**Adryan Fristiohady**  
Universitas Halu Oleo, Indonesia  
**Prayasee Baruah**  
North-Eastern Hill University, India  
**Santwana Palai**  
Odisha University of Agriculture and  
Technology, India  
**Saeiful Amin**  
Sekolah Tinggi Ilmu Kesehatan Bakti Tunas  
Husada, Indonesia  
**Hasyrul Hamzah**  
Universitas Muhammadiyah Kalimantan  
Timur, Indonesia

**Nurolaini Kifli**  
Universiti Brunei Darussalam, Brunei Darussalam  
**Alexandru Mihai Grumezescu**  
Politechnica University of Bucharest, Romania  
**Anna Vladimirovna Kurkina**  
Samara State Medical University, Russia  
**A Lalithamma**  
Karpaga Vinayaga Institute of Medical Sciences, India  
**Julaeha**  
Universitas 17 Agustus 1945 Jakarta, Indonesia  
**Ihsanul Arief**  
Akademi Farmasi Yarsi Pontianak, Indonesia  
**Mohammed Gamal**  
Jouf University, Saudi Arabia  
**Dian Wuri Astuti**  
Sekolah Tinggi Ilmu Kesehatan Guna Bangsa  
Yogyakarta, Indonesia  
**Monaj Kumar Sarkar**  
Shanmugha Arts, Science, Technology and Research  
Academy (SASTRA) Deemed University, India  
**Hafsan**  
Universitas Islam Negeri Alauddin Makassar,  
Indonesia

**Mahendran Sekar**  
Universiti Kuala Lumpur, Malaysia  
**Punet Kumar**  
Shri Gopichand College of Pharmacy, India  
**Rimadani Pratiwi**  
Universitas Padjadjaran, Indonesia  
**Ruqiah Ganda Putri Panjaitan**  
Universitas Tanjungpura, Indonesia  
**Sutomo**  
Universitas Lambung Mangkurat, Indonesia  
**Arnida**  
Universitas Lambung Mangkurat, Indonesia  
**Andhika Bintang Mahardhika**  
Institut Teknologi Bandung, Indonesia  
**Isna Rasdianah Aziz**  
Universitas Islam Negeri Alauddin  
Makassar, Indonesia  
**Dhafer Saber Zinad**  
University of Technology, Iraq  
**Paula Mariana Kustiawan**  
Universitas Muhammadiyah Kalimantan  
Timur, Indonesia

## COVER & LAYOUT DESIGN

Syahrida Dian Ardhany

## PUBLISHED BY



**Institute for Research and Community Services**  
Universitas Muhammadiyah Palangkaraya  
RTA Milono St. Km. 1,5 Palangka Raya 73111  
[bjop@umpr.ac.id](mailto:bjop@umpr.ac.id)  
<https://journal.umpr.ac.id/index.php/bjop>

## EDITORIAL WORDS

*apt. Mohammad Rizki Fadhil Pratama, S.Farm., M.Si.*

*Editor in Chief  
Borneo J Pharm*

*Assalamu'alaikum Wr. Wb.*

Alhamdulillahirabbil 'alamin. The next edition of **Borneo Journal of Pharmacy** (*Borneo J Pharm*), has been published at February 2024. This edition contains ten articles: Pharmacognosy-Phytochemistry, Analytical Pharmacy-Medicinal Chemistry, and Clinical-Community Pharmacy. This edition includes writings from four countries: India, Indonesia, South Africa, and Thailand. The authors come from several institutions, including Universitas Muhammadiyah Kalimantan Timur, Universitas Gadjah Mada, Khon Kaen University, Universitas Muhammadiyah Surakarta, University of the Witwatersrand, Universitas Sanata Dharma, Universitas Halu Oleo, Universitas Bhakti Kencana, Universitas Negeri Gorontalo, Sekolah Tinggi Farmasi Mahaganasha, Universitas Tanjungpura, National Research and Innovation Agency of the Republic of Indonesia, Universitas Surabaya, Universitas Airlangga, Universitas Indonesia, M. S. Ramaiah University of Applied Sciences, and Universitas Muhammadiyah Yogyakarta.

Editorial boards are fully aware that there are still room for improvement in this edition, hence with all humility willing to accept constructive suggestions and feedback for improvements to the publication for the next editions. The editorial board would like to thank all editors and reviewers, and contributors of the scientific articles who have provided the repertoire in this issue. We hope that all parties, especially the contributors, could re-participate for the publication in the next edition on May 2024.

*Wassalamu'alaikum Wr. Wb.*

Palangka Raya, February 2024

Editor-in-Chief

# Table of Contents

## BORNEO JOURNAL OF PHARMACY

Borneo J Pharm – e-ISSN: 2621-4814

Volume 7 Issue 1 February 2024

### Sections: PHARMACOGNOSY-PHYTOCHEMISTRY

#### **Nanoemulsion Mouthwash Formulation of Bajakah Tampala (*Spatholobus littoralis* Hassk.) Skin Extract Against *Candida albicans***

**Hasyrul Hamzah** / Universitas Muhammadiyah Kalimantan Timur & Indonesian Biofilm Research Collaboration Center, Indonesia

**Dede Reza Gunawan** / Universitas Muhammadiyah Kalimantan Timur & Indonesian Biofilm Research Collaboration Center, Indonesia

**Sylvia Utami Tunjung Pratiwi** / Universitas Gadjah Mada & Indonesian Biofilm Research Collaboration Center, Indonesia

**Muh. Irham Bakhtiar** / Universitas Muhammadiyah Kalimantan Timur & Indonesian Biofilm Research Collaboration Center, Indonesia

**Virgiawan Yoga Pratama** / Universitas Muhammadiyah Kalimantan Timur & Indonesian Biofilm Research Collaboration Center, Indonesia

**Muhammad Subhan** / Khon Kaen University, Thailand

**Riza Maulana** / Universitas Muhammadiyah Surakarta, Indonesia

1 – 13

#### **Comparative Phytochemical Profiling and Biological Activities in the Flowers and Stalks of *Tulbaghia violacea***

**Gontse Maleka** / University of the Witwatersrand, South Africa

**Rebecca Opeyemi Oyerinde** / University of the Witwatersrand, South Africa

**Ida Masana Risenga** / University of the Witwatersrand, South Africa

14 – 28

### Sections: ANALYTICAL PHARMACY-MEDICINAL CHEMISTRY

#### **Genetic CYP2A6 Polymorphism May Worsen Glycohemoglobin Levels: Study among Javanese Indonesian Smokers**

**Christine Patramurti** / Universitas Sanata Dharma, Indonesia

**Dita Maria Virginia** / Universitas Sanata Dharma, Indonesia

29 – 39

#### **Marine Sponge *Xestospongia* sp.: A Promising Source for Tuberculosis Drug Development - Computational Insights into Mycobactin Biosynthesis Inhibition**

**Arfan** / Universitas Halu Oleo, Indonesia

**Aiyi Asnawi** / Universitas Bhakti Kencana, Indonesia

**La Ode Aman** / Universitas Negeri Gorontalo, Indonesia

40 – 50

### Sections: NATURAL PRODUCT DEVELOPMENT

#### **Total Flavonoid Levels in *n*-hexane and Ethyl Acetate Fractions of *Rosmarinus officinalis* L. Leaves and Their Antibacterial and Antioxidant Activities**

**Ni Ketut Esati** / Sekolah Tinggi Farmasi Mahaganesha, Indonesia

**Elisabeth Oriana Jawa La** / Sekolah Tinggi Farmasi Mahaganesha, Indonesia

**Ni Putu Sudiasih** / Sekolah Tinggi Farmasi Mahaganesha, Indonesia

**Ni Nyoman Dina Saniasih** / Sekolah Tinggi Farmasi Mahaganesha, Indonesia

51 – 62

**Potential of Indonesian Plants as Polymicrobial Anti-Biofilm**

**Rafika Sari** / Universitas Gadjah Mada & Universitas Tanjungpura, Indonesia

**Sylvia Utami Tunjung Pratiwi** / Universitas Gadjah Mada, Indonesia

**Yosi Bayu Murti** / Universitas Gadjah Mada, Indonesia

**Ema Damayanti** / Universitas Gadjah Mada, Indonesia

63 - 79

**An Initial Investigation of the Potential of Robusta Coffee, Arabica Coffee, and Caffeine in Asthma Treatment through the Evaluation of 5-Lipoxygenase Inhibition Activity**

**Tegar Achsendo Yuniarta** / Universitas Surabaya, Indonesia

**Rosita Handayani** / Universitas Airlangga & Universitas Indonesia, Indonesia

80 - 88

**Ziziphus rugosa Leaves: Pharmacognostical Characters and Anti-Inflammatory Properties against Carrageenan-Induced Paw Edema**

**Enugurthi Hari Krishna** / M. S. Ramaiah University of Applied Sciences, India

**Kamatchi Sundara Saravanan** / M. S. Ramaiah University of Applied Sciences, India

**Judy Jays** / M. S. Ramaiah University of Applied Sciences, India

89 - 103

Sections: **CLINICAL-COMMUNITY PHARMACY**

**Appropriateness and Cost of Prophylaxis Stress Ulcer for Inpatient in the Internal Medicine Department in a Government Hospital: A Cross-Sectional Study**

**Mega Octavia** / Universitas Muhammadiyah Yogyakarta, Indonesia

**Nurul Maziyah** / Universitas Muhammadiyah Yogyakarta, Indonesia

**Rima Nurul Fauziah** / Universitas Muhammadiyah Yogyakarta, Indonesia

104 - 111

**Development and Validation of a Questionnaire for the Assessment of the Factors that Influence ADR Reporting by Pharmacists**

**Favian Rafif Firdaus** / Universitas Airlangga, Indonesia

**Yunita Nita** / Universitas Airlangga, Indonesia

**Catur Dian Setiawan** / Universitas Airlangga, Indonesia

**Elida Zairina** / Universitas Airlangga, Indonesia

112 - 125

## Author Guidelines

# BORNEO JOURNAL OF PHARMACY

*Borneo J Pharm* – e-ISSN: 2621-4814

1. Writing is the result of research or review of critical analysis study in the field but not limited to Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Pharmaceutical, Analytical Pharmacy-Medicinal Chemistry, Natural Product Development, Clinical-Community Pharmacy, Management Pharmacy, and other Pharmacy aspects which have never been published in other scientific publication media.
2. Manuscripts that have been published in the form of a preprint on several platforms such as arXiv, INA-RXiv, SSRN, and ResearchGate are welcome to publish.
3. The manuscript is written in English with Book Antiqua font 10 pt, two-column, density 1.15 spaces, on A4 paper with a top-down margin of 2.5 cm and right-left margins 1.5 cm.
4. The manuscript is typed with MS-Word program using the provided template and saved in .doc or .docx format.
5. The manuscript is typed strictly with the following rules:
  - a. The title, short and clear, written in English. The title length does not exceed 20 words.
  - b. Authors, listed without mention of title or degree, under the name including the affiliation and complete address, and email of the corresponding author. The author's name, which consists of one word, must be repeated twice for first and last names. To author with names of more than two words, the author's last name consists of only one word, the rest is written as the first name.
  - c. Abstract, written in English which is a summary of the article. The abstract is created in one paragraph and a maximum of 250 words with Book Antiqua font 9 pt, single column, and space 1. Points that must be listed in the abstract include the research objectives, methods, results, conclusions, and keywords. The number of keywords is between three and five keywords.
  - d. Introduction, contain background, reasons for the importance of underlying research or hypotheses, general approaches and objectives of the research and relevant literature review. The number of paragraphs not restricted but the contents must include background, objectives, positions on previous research, as well as the novelty of the research. The little theoretical basis which indirectly related to the contents of the article could be included without sub-chapters required. Citation is written in occurrence number on the manuscript (Vancouver style).
  - e. Methodology, Research method consists of 2 sub-chapters including materials and methods. If data analysis is specific, or the way of analysis is novel, then data analysis subchapter could be added. The sub-chapters are written without numbering or bullet.
  - f. Results and Discussion, at least contain three subjects (1) description of results, (2) interpretation or explanation of results, and (3) comparative of results with previous studies results. If the subchapters very length could be made sub-sub-chapters with Arabic numbering. Description of the results can be in the form of tables and figures with a serial number (Table uses a sequence of Roman numerals and placed at the top, while figures using Arabic numeric sequence and placed in the below).
  - g. Conclusion, made in a single paragraph without the citation contains the final conclusion and suggestions for advanced research.
  - h. References, a list of recently selected topics is published last five years (the minimum percentage and a minimum number of references are different for each type of manuscript). The bibliography is written in chronological order with the serial number (Vancouver style) and suggested using a reference management application such as EndNote, Mendeley, Zotero, and other applications.
6. Authors whose manuscripts are published are free of charge for both Publication cost and article processing charge.
7. Authors will get full access to the article published on e-journal of Universitas Muhammadiyah Palangkaraya at the website <https://journal.umpr.ac.id/index.php/bjop>.


# BJOP

Borneo Journal of  
.....  
**PHARMACY**

Volume 7 Issue 1 February 2024



9 772621 481001



## Genetic CYP2A6 Polymorphism May Worsen Glycohemoglobin Levels: Study among Javanese Indonesian Smokers

Christine Patramurti <sup>1\*</sup>   

Dita Maria Virginia <sup>2</sup>   

<sup>1</sup> Department of Pharmaceutical Chemistry, Universitas Sanata Dharma, Sleman, Yogyakarta Special Region, Indonesia

<sup>2</sup> Department of Pharmacology and Clinical Pharmacy, Universitas Sanata Dharma, Sleman, Yogyakarta Special Region, Indonesia

\*email: [patra@usd.ac.id](mailto:patra@usd.ac.id); phone: +628129800913

### Keywords:

CYP2A6\*4  
CYP2A6\*7  
CYP2A6\*9  
HbA1c levels

### Abstract

We have examined the inactive CYP2A6 alleles gene, including CYP2A6\*4, CYP2A6\*7, and CYP2A6\*9, associated with glycohemoglobin levels among Javanese Indonesian smokers. There are 106 smokers participating in this study. Due to the number of cigarettes smoked per day, there are three groups of smokers: light, intermediate, and heavy smokers, with 98.7% being light and intermediated smokers while the rest are heavy smokers. All participants had smoked for more than 10 years, indicating they had been exposed to nicotine for a long time. Based on their genotype, there were four groups of smokers, including fast, intermediate, slow, and poor metabolizers. Most fast and intermediate metabolizers have HbA1c levels in the normal range (<5.7). On the other hand, most slow metabolizers have Hb1c levels >5.7, and all fast metabolizers have HbA1c levels >5,7, indicating that they the prediabetes and diabetes. The chi-square test showed a relationship between CYP2A6 polymorphism and HbA1c levels among the participants (P-value 0.000 <0.005 and  $\chi^2=54.6$ ,  $df=1$ ). The presence of an inactive allele will worsen the HbA1c levels in smokers.

Received: July 19<sup>th</sup>, 2023

1<sup>st</sup> Revised: January 24<sup>th</sup>, 2024

Accepted: February 13<sup>th</sup>, 2024

Published: February 29<sup>th</sup>, 2024



© 2024 Christine Patramurti, Dita Maria Virginia. Published by Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya. This is an Open Access article under the CC-BY-SA License (<http://creativecommons.org/licenses/by-sa/4.0/>). DOI: <https://doi.org/10.33084/bjop.v7i1.5467>

## INTRODUCTION

Diabetes mellitus (DM), a chronic disease, was the third leading cause of death in Indonesia, with a percentage of 6.7% after stroke (21.1%) and coronary heart disease (12.9%). The DM prevalence in Indonesia has increased substantially from 6.9% in 2013 to 8.5% in 2018<sup>1</sup>. Other data has estimated that approximately 30% of Indonesia's population (30 million people) with diabetes remains undiagnosed. The diabetics in Indonesia were estimated could reach 30 million people in 2030 if lifestyles including unhealthy diet, obesity, lack of physical activity, alcohol consumption, and smoking are not a concern<sup>2</sup>. In line with this report, The International Diabetes Federation (IDF) found that people with diabetes in Indonesia have increased precipitously in the last ten years from 2021. Without proper management, people with diabetes will jump to a staggering 28.57 million in 2045, or 47% greater than 19.47 million in 2021<sup>3</sup>.

Type 2 diabetes mellitus (T2DM) is the most common in adults and accounts for 90% of all diabetes cases. In past years, T2DM typically develops in adulthood. However, in recent years, it has been increasingly seen in children and adolescents partially due to lifestyle, including rising obesity rates, unhealthy diet, lack of physical inactivity, alcohol consumption, and smoking<sup>4</sup>. The Basic Health Research of Indonesia (*Riset Kesehatan Dasar, RISKESDAS*) 2018 reports that T2DM prevalence in the Daerah Istimewa Yogyakarta (DIY) Province was second among provinces in Indonesia<sup>5</sup>. About 74,668 DIY people have been diagnosed with diabetes, but only 55,190 patients have received standard health services or the equivalent of 73.9%<sup>6</sup>.

Several studies have suggested that poor smoking behavior is associated with chronic complications of T2DM compared to non-smokers<sup>7,8</sup>. Another study has reported that smoking can increase glycohemoglobin (HbA1c) blood levels<sup>9</sup>. This HbA1c value can accurately reflect glucose control 2-3 months ago. HbA1c levels are normal if <5.7%, prediabetes 5.7 to 6.4%, and



diabetes  $\geq 6.5\%$ <sup>10</sup>. Nicotine, the main compound in cigarettes, was considered most responsible for increasing blood sugar levels due to insulin resistance<sup>11</sup>.

Nicotine is primarily metabolized by the CYP2A6 enzyme to cotinine and excreted in the urine<sup>12</sup>. The CYP2A6 enzyme encoded by the CYP2A6 gene is a polymorphic gene. The active allele gene is CYP2A6\*1, and the inactive is CYP2A6\*4, CYP2A6\*7, and CYP2A6\*9. Due to their genotype, a person with having CYP2A6\*4, CYP2A6\*7, and CYP2A6\*9 allele genes is associated with a slow metabolizer or poor metabolizer<sup>13</sup>. Furthermore, according to Liu *et al.*<sup>14</sup>, reduced metabolism function CYP2A6 in smokers appears to be associated with a higher risk of T2DM.

Our preliminary study<sup>15</sup> revealed a high-frequency CYP2A6\*4 allele gene among smokers and non-smokers in Javanese Indonesian. We have also reported that smoking can increase diabetes risk factors. Prediabetes was developing in smokers who had smoked for at least 25 years with 25 cigarettes per day<sup>16</sup>. Furthermore, in our recent study on diabetic patients, both smokers and non-smokers, high-frequency CYP2A6\*4, the inactive allele gene of CYP2A6, was detected<sup>17</sup>. In high frequency, the other inactive alleles, CYP2A6\*7 and CYP2A6\*9, have also been found among Javanese Indonesian smokers<sup>13</sup>. So, in this research, we study the association of the CYP2A6\*4, CYP2A6\*7, and CYP2A6\*9 on glycohemoglobin levels in Indonesian Javanese smokers.

## MATERIALS AND METHODS

### Materials

A Norudia® N HbA1c Immunoassay Method using the Architect 600 instrument, calibrated using Diabetes Control and Complications Trial (DCCT) standards with a coefficient of variation  $< 2.5\%$  was used to analyze total HbA1c in the Clinical Pathology Laboratory, Bethesda Hospital, Yogyakarta. Genomic DNA was extracted using a DNA Mini Kit from Bioron GmbH (Germany). The CYP2A6\*4, \*7, and \*9 allele genes were analyzed using the Polymerase Chain Reaction (PCR) method. The forward and reverse primers used in this study were 5' CCT CAT CAC ACA CAA CTT CCT C 3' and 5' TGC AGG TAC TGG GTG CTT GGT AG 3' for CYP2A6\*4; 5'-CTC CCA GTC ACC TAA GGA CAC-3' and 5'-AAA ATG GGC ATG AAC GCC C-3' for CYP2A6\*7; as well as 5'-GAT TCC TCT CCC CTG GAA C-3' and 5'-GGC TGG GGT GGT TTG CCT TTC-3' for CYP2A6\*9.

The PCR mixture contained 12.5  $\mu$ L Promega Go Taq Green Master Mix, 1.25  $\mu$ L forward primer, 1.25  $\mu$ L reverse primer, 5.0  $\mu$ L genomic DNA, and 5.0  $\mu$ L nuclease-free water in a final volume of 25  $\mu$ L. This mixture was run using a PCR machine (Thermal cycler Perkin Elmer 2400) to amplify the genomic DNA. The PCR conditions used are shown in [Table I](#).

**Table I.** PCR condition used.

PCR Condition	Allele gene		
	CYP2A6*4	CYP2A6*7	CYP2A6*9
Initial denaturation	95°C (5')	95°C (5')	94°C (3')
Denaturation	98°C (20'')	95°C (20'')	94°C (30'')
Annealing	64°C (15'')	56.5°C (30'')	60°C (30'')
Extention	72°C (30'')	72°C (30'')	70°C (25'')
Cycle	30	35	35
Final extention	72°C (5')	72°C (5')	72°C (5')

### Methods

#### Research subject

It is an observational study using a cross-sectional design to analyze the CYP2A6 polymorphism among Javanese Indonesian Smokers associated with glycohemoglobin blood levels, the main predictor for diabetes disease. Participants were enrolled between July and August 2022. They live in Yogyakarta, as indicated by their identity card. A preliminary survey was conducted to find respondents who smoked using a self-reported smoking questionnaire adopted from the Fagerström Test for Nicotine Dependence (FTND) questionnaire<sup>18</sup>. The participants had to meet the study's inclusion criteria: active smokers who had smoked for at least ten years, Javanese Indonesians with at least three grandparents of Javanese descent due to their self-reported, male, aged 20-50 years, weight between 46 to 75 kg, with a varying height between 150-170 cm. This study excluded the participant who had an infection at the blood sampling and was taking an

anticoagulant. All participants had agreed to participate in this study indicated by signing the informed consent. The study was approved by the Ethics Commission for General Medicine Research, Universitas Duta Wacana, Yogyakarta (No. 1413/C.16/FK/2022).

#### Blood sample collection

Three mL of blood was sampled from a cubital vein in all participants who had met the inclusion and exclusion criteria. Blood samples were collected in a vacutainer containing EDTA (1.8 mg/mL blood) and immediately stored in the refrigerator at 4°C.

#### PCR analysis

The PCR products were analyzed using electrophoresis with 1.5% agarose and evaluated using a UV transilluminator. Expressed PCR products are documented using a Polaroid camera.

#### Data analysis

To describe the study population and evaluate data, we used Microsoft Excel 2019. All values are displayed as the mean  $\pm$ SD or number (%). We assumed  $p < 0.05$  indicated significant differences. Using a box plot diagram, we also described the distribution of HbA1c levels among the subjects based on their CYP2A6 allele gene. The chi-square test was used to analyze the relationship between CYP2A6 polymorphism and HbA1c levels.

## RESULTS AND DISCUSSION

A total of 106 participants were participating in this study. There are three groups of test subjects, based on the number of cigarettes per day (CPD) they smoked: light smokers (CPD: 1-10), intermediate smokers (CPD: 11-20), and heavy smokers (CPD: 21-30)<sup>19</sup>. All the respondents were smoking a white filter cigarette containing 12 mg of nicotine/cigarette. **Table II** below shows the respondent characteristics participating in this study. Based on **Table II**, 88.7% of the respondents are light and intermediate smokers, while 11.3% are heavy smokers. The Ministry of Health of the Republic of Indonesia has reported that the average CPD by Indonesian adults was 13 cigarettes or the equivalent of one pack<sup>6</sup>. Some of the respondents started smoking at the age of under ten years. Several factors influence smoking behavior among children and adolescents, including easy access to cigarettes, family and peer environment, and cigarette promotion/advertising<sup>20</sup>. All respondents had smoked for at least ten years, indicating that they had been exposed to nicotine for a long time.

**Table II.** Respondent characteristics.


Characteristics	Smoking Status			Total
	Light	Intermediate	Heavy	
<b>Number (%)</b>	43 (40.6)	51 (48.1)	12 (11.3)	106
<b>Age</b>				
Mean $\pm$ SD	44.4 $\pm$ 9.5	43.6 $\pm$ 11.7	45.0 $\pm$ 8.2	47.2 $\pm$ 12.9
Range	32 - 71	29 - 78	37 - 62	29 - 78
<b>First age smoking</b>				
Mean $\pm$ SD	18.5 $\pm$ 3.8	17.2 $\pm$ 3.0	14.1 $\pm$ 6.2	17.3 $\pm$ 3.4
Range	13 - 30	13 - 27	10 - 16	10 - 27
<b>Smoking duration</b>				
Mean $\pm$ SD	26.3 $\pm$ 9.8	26.5 $\pm$ 11.7	29.8 $\pm$ 7.1	30.1 $\pm$ 12.5
Range	14 - 51	13 - 63	24 - 46	13 - 63
<b>CPD</b>				
Mean $\pm$ SD	8 $\pm$ 2	14 $\pm$ 2	24 $\pm$ 3	13 $\pm$ 5
Range	3 - 10	11 - 20	21 - 30	3 - 30

Several studies have proven that cigarette dependence can trigger the occurrence of T2DM<sup>21,22</sup>. Compared to non-smokers, active smokers have a 76% higher risk of developing T2DM<sup>23,24</sup>. Nicotine in cigarette smoke was responsible for the development of T2DM in smokers<sup>25-27</sup>. Nicotine in cigarettes has caused insulin resistance and reduced insulin secretion<sup>28</sup>. Xie *et al.*<sup>29</sup> has revealed that nicotine exposure in the long term will decrease insulin secretion through the activation of nAChRs present in pancreatic cells. Furthermore, Xie *et al.*<sup>29</sup> also mentioned that nicotine exposure for a short period (24

hours) will inhibit insulin release from the pancreas. Other studies have shown that nicotine exposure can cause pancreatic cell dysfunction and increased cell apoptosis<sup>30,31</sup>. Eventually, it will cause an increase in blood glucose levels and the T2DM risk factor in smokers<sup>7</sup>.

Our study assesses the T2DM risk factor in smokers using the HbA1c blood level. Several studies have used the HbA1c parameter to control blood glucose levels<sup>8,16,23,32</sup>. Indonesian Endocrinology Society (*Perkumpulan Endokrinologi Indonesia, PERKENI*) stated that people with HbA1c levels <6.5 have a normal glucose level. People with HbA1c levels between 5.7% and 6.4% have prediabetes and a higher chance of getting diabetes. The diabetes condition is established if the HbA1c levels are higher than 6.5%<sup>33</sup>. Akkuzulu *et al.*<sup>23</sup> has reported a positive correlation between nicotine dependence and HbA1c levels in smokers. Several other previous studies have also revealed that compared to non-smokers, smokers have higher HbA1c levels and a 30-40% higher risk of T2DM<sup>8,34</sup>. Somm *et al.*<sup>31</sup> has revealed that nicotine administration in low doses will increase HbA1c levels by 8.8%, and at high doses, after being given nicotine for two days, increase HbA1c levels by 34.5%.

**Figure 1** describes the distribution of HbA1c levels among the respondents. According to **Figure 1**, 16.04% of the respondents participating in this study had diabetes, and 13.16% were pre-diabetic. They are mainly distributed among intermediate and heavy smokers with smoking for more than 20 years. It is in line with our previous study that prediabetes among Javanese smokers will occur at a minimum CPD of 20 cigarettes with a minimum smoking duration of 25 years. Meanwhile, diabetes will occur at a minimum CPD of 20 cigarettes with a minimum smoking duration of 29 years<sup>16</sup>. Therefore, it is possible for respondents whose HbA1c levels <5.7 will still develop T2DM if they continue to smoke. Diabetes was an underdiagnosed disease. Approximately 30% of diabetics are often unaware of their condition, resulting in 25% of people with diabetes being diagnosed with microvascular complications. The average delay from onset to diagnosis is about seven years<sup>35</sup>. This study has also supported the report issued by *RISKESDAS* 2018, that only about 25% of diabetics in Indonesia know that they have diabetes<sup>36</sup>.



**Figure 1.** The HbA1c distribution among participants.

In addition, another factor that can increase the T2DM risk in a smoker is the *CYP2A6* polymorphism. The three *CYP2A6* inactive allele genes have been identified in this study: *CYP2A6*\*4, \*7, and \*9. The *CYP2A6*\*4, a whole gene deletion, due to the unequal crossover junction with *CYP2A7*. *CYP2A6*\*7 occurred due to the Single Nucleotide Polymorphism (SNPs) in the 8454<sup>th</sup> nucleotide base sequence (T>C). The *CYP2A6*\*9 allele formed due to the SNPs in the TATA box in the *CYP2A6* promoter region at the -48T>G point<sup>37</sup>. These three allele genes will decrease the *CYP2A6* enzyme activity, either intermediate, slow, or poor metabolizer. Smokers with slow or poor metabolizers are more susceptible to suffering T2DM than fast metabolizers<sup>38</sup>.


**Table III** shows that the *CYP2A6*\*4, *CYP2A6*\*7, and *CYP2A6*\*9 allele frequency were 50.9%, 4.3%, and 3.8%, respectively. It is consistent with our previous studies<sup>15,16</sup>, where the *CYP2A6*\*4 allele frequency in Javanese was high. These allele genes will decrease the *CYP2A6* enzyme activity. Several studies<sup>39-41</sup> have revealed that smokers with the inactive allele would slowly metabolize the nicotine compared to the active allele. Consequently, the nicotine blood level becomes higher, and the

CPD and nicotine dependence become lower. Based on the three allele genes, Peamkrasatam *et al.*<sup>42</sup> and Malaiyandi *et al.*<sup>43</sup> classified the CYP2A6 phenotype into four groups: fast metabolizer (CYP2A6\*1/\*1), intermediate metabolizer (CYP2A6\*1/\*4; CYP2A6\*1/\*7, CYP2A6\*1/\*9), slow metabolizer (CYP2A6\*4/\*7; CYP2A6\*4/\*9, CYP2A6\*7/\*9), and poor metabolizer (CYP2A6\*4/\*4). As shown in Table III, only four (3.8%) smokers are fast metabolizers, and most smokers are intermediate metabolizers (74.5%), while the rest are slow and poor metabolizers (21.7%).

**Table III.** CYP2A6 genotype and allele frequency among respondents.

Allele	Frequency (n = 212)	Genotype	Frequency (n = 106)
CYP2A6*1	41% (87)	CYP2A6*1/*1	3.8% (4)
CYP2A6*4	50.9% (108)	CYP2A6*1/*4	74.5% (79)
CYP2A6*7	4.3% (9)	CYP2A6*4/*7	8.5% (9)
CYP2A6*9	3.8% (8)	CYP2A6*4/*9	7.5% (8)
		CYP2A6*4/*4	5.7% (6)
<b>Total</b>	<b>100%</b>	<b>Total</b>	<b>100%</b>

Figure 2 describes the distribution of HbA1c levels among the respondent based on their phenotype. Figure 2 shows that all participants with fast metabolizers and most intermediate metabolizers had HbA1c levels <5.7. There are only 10 participants with intermediate metabolizers had HbA1c >5.7. In the slow metabolizer, two people have HbA1c values <5.7, and the rest have >5.7. On the other hand, all participants with poor metabolizers have HbA1c levels >5.7, indicating that they have diabetes condition. It is in line with another study<sup>44</sup> that heavy smokers with slow and poor metabolizers would have a high risk of developing T2DM compared to light smokers with fast and intermediate metabolizers. Furthermore, we used a chi-square test to analyze the effect of the inactive alleles on the HbA1c levels among the participants.



**Figure 2.** HbA1c levels distribution among the test subjects according to their genotype. FM: fast metabolizers; SM: slow metabolizers; IM: intermediate metabolizers; PM: poor metabolizers.

As shown in **Table IV**, due to its p-value ( $0.000 < 0.005$ ) and  $\chi^2$  (54.6) with  $df=1$ , it is known that *CYP2A6* polymorphism could have affected the HbA1c levels among the participants. The homozygous and heterozygous \*4, \*7, and \*9 among smokers would increase the risk of HbA1c levels in smokers. *CYP2A6* enzyme encoded by *CYP2A6* is the enzyme corresponding to nicotine inactivation. The inactive metabolites of nicotine excreted in the urine are cotinine and trans-3-hydroxycotinine<sup>45</sup>. Therefore, heavy smokers with slow or poor metabolizers tend to have higher nicotine plasma levels than light smokers with fast or intermediate metabolizers. Several studies have revealed that smokers may increase the risk of T2DM, indicated by an increase in HbA1c levels. It is due to pancreatic  $\beta$  cell dysfunction and insulin resistance<sup>34,46</sup>.

**Table IV.** The relationship between *CYP2A6* polymorphism to HbA1c values among participants.

CYP2A6 polymorphism	HbA1c levels (n, %)		Total	p-value (V)	$\chi^2$ (df)
	<5.7	>5.7			
Homozygote *1/*1 and heterozygote *1/*4	73 (88%)	10 (12%)	83 (100%)	0.000 (0.718)	54.6 (1)
Homozygote and heterozygote *4, *7, *9	2 (8.7%)	21 (91.3%)	23 (100%)		
<b>Total</b>	<b>75 (70.8%)</b>	<b>31 (29.2%)</b>	<b>106 (100%)</b>		

*CYP2A6* is also known as the enzyme responsible for nitrosamine metabolic activation, the pre-carcinogen compound in tobacco smoke, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), *N'*-nitrosonornicotine (NNN), *N'*-nitrosoanabasine (NAB), and *N'*-nitrosoanatabine (NAT)<sup>47</sup>. Therefore, smokers with slow or poor metabolizers could reduce the hepatic first-pass clearance of tobacco nitrosamines, resulting in greater exposure to other organs, such as the pancreas, due to its higher systemic levels<sup>48</sup>. The increased exposure of nitrosamine in pancreatic islet cells could lead it's the metabolic activation by other cytochrome P450 enzymes (CYPs), including *CYP2E1*<sup>47</sup>, resulting in inflammation and apoptosis of pancreatic cells, which is furthermore might decrease insulin secretion and the increased risk of developing T2DM<sup>49</sup>.

According to Bergman *et al.*<sup>50</sup>, insulin sensitivity will recover in a smoker who has quit smoking; therefore, to prevent diabetes, a smoker must stop smoking. It is also supported by other studies<sup>51-53</sup> on preventing T2DM among smokers through smoking cessation strategies. Several studies<sup>54-56</sup> have also shown that smokers who have inactive alleles tend to quit smoking more easily. Therefore, to increase efforts to reduce the prevalence of diabetes in Indonesia, cooperation from various parties is needed to reduce cigarette consumption in Indonesia. *RISKESDAS* in Indonesia has reported that the number of smokers over 15 years of age was 33.8%, of which 62.9% were male and 4.8% were female<sup>57</sup>. In addition, The Southeast Asia Tobacco Control Alliance (SEATCA) in The Tobacco Control Atlas has reported that the number of smokers in Indonesia was 65.19 million, placing Indonesia as the highest number in Southeast Asia<sup>58</sup>. Therefore, based on our study, we suggest promoting smoking cessation campaigns is the best effort to reduce cigarette consumption and diseases related to cigarettes, such as T2DM, stroke, and coronary heart disease.

Quite a few limitations of our study are: this was a cross-sectional study, the causal association between *CYP2A6* polymorphism and HbA1c levels should be interpreted carefully; we used self-report surveys to collect the data regarding smoking behavior, thus it might have been caused bias data; the other inactive allele of *CYP2A6* might be reduced *CYP2A6* activity resulting in the alteration of phenotype, primarily on fast and intermediate metabolizers; and some confounding factor, including obesity, physical activity, and dietary factors have not fully accounted in our analysis.

## CONCLUSION

In conclusion, this study reveals that the heterozygote *CYP2A6* alleles, including \*4, \*7, and \*9, corresponding to slow and poor metabolizers, may worsen HbA1c levels among Javanese Indonesian smokers. Furthermore, due to our result, it may be crucial for the government to encourage smoking cessation programs in Indonesia, which are trusted to prevent various health problems, especially diseases related to smoking behavior, including T2DM, stroke, and coronary heart disease.

## ACKNOWLEDGMENT

This study was supported by the Institute of Research and Community Services Universitas Sanata Dharma (No. 017 Penel./LPPMUSD/IV/2022).

## AUTHORS' CONTRIBUTION

**Conceptualization:** Christine Patramurti  
**Data curation:** Christine Patramurti  
**Formal analysis:** Christine Patramurti  
**Funding acquisition:** Christine Patramurti  
**Investigation:** Dita Maria Virginia  
**Methodology:** Dita Maria Virginia  
**Project administration:** Dita Maria Virginia  
**Resources:** Christine Patramurti  
**Software:** -  
**Supervision:** Christine Patramurti  
**Validation:** Christine Patramurti  
**Visualization:** Dita Maria Virginia  
**Writing - original draft:** Christine Patramurti  
**Writing - review & editing:** Dita Maria Virginia

## DATA AVAILABILITY

None.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## REFERENCES

1. Wahidin M, Achadi A, Sitorus N, Handayani R. Overview of Diabetes Mellitus and its Risk Factors in Indonesia: An Analysis of Basic Health Research Data. *Southeast Asian J Trop Med Public Health*. 2022;53(Suppl 2):642-59.
2. Siregar FA, Asfriyati, Makmur T, Bestari R, Lubis IA, Zein U. Identifying Adult Population at Risk for Undiagnosed Diabetes Mellitus in Medan City, Indonesia Targeted on Diabetes Prevention. *Med Arch*. 2023;77(6):455-9. DOI: [10.5455/medarh.2023.77.455-459](https://doi.org/10.5455/medarh.2023.77.455-459); PMID: [38313111](https://pubmed.ncbi.nlm.nih.gov/38313111/); PMCID: [PMC10834042](https://pubmed.ncbi.nlm.nih.gov/PMC10834042/)
3. Prabowo MH, Febrinasari RP, Pamungkasari EP, Mahendradhata Y, Pulkki-Brännström AM, Probandari A. Health-related Quality of Life of Patients with Diabetes Mellitus Measured With the Bahasa Indonesia Version of EQ-5D in Primary Care Settings in Indonesia. *J Prev Med Public Health*. 2023;56(5):467-74. DOI: [10.3961/jpmph.23.229](https://doi.org/10.3961/jpmph.23.229); PMID: [37828874](https://pubmed.ncbi.nlm.nih.gov/37828874/); PMCID: [PMC10579634](https://pubmed.ncbi.nlm.nih.gov/PMC10579634/)
4. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. *Int J Mol Sci*. 2020;21(17):6275. DOI: [10.3390/ijms21176275](https://doi.org/10.3390/ijms21176275); PMID: [32872570](https://pubmed.ncbi.nlm.nih.gov/32872570/); PMCID: [PMC7503727](https://pubmed.ncbi.nlm.nih.gov/PMC7503727/)
5. Arifin H, Chou KR, Ibrahim K, Fitri SUR, Pradipta RO, Rias YA, et al. Analysis of Modifiable, Non-Modifiable, and Physiological Risk Factors of Non-Communicable Diseases in Indonesia: Evidence from the 2018 Indonesian Basic Health Research. *J Multidiscip Healthc*. 2022;15:2203-21. DOI: [10.2147/jmdh.s382191](https://doi.org/10.2147/jmdh.s382191); PMID: [36213176](https://pubmed.ncbi.nlm.nih.gov/36213176/); PMCID: [PMC9532265](https://pubmed.ncbi.nlm.nih.gov/PMC9532265/)
6. Patramurti C, Virginia DM, Fenty F, Setiawan CH, Julianus J, Hendra P, et al. High Frequency of CYP2A6\*4, CYP2A6\*7, and CYP2A6\*9 Alleles Detected Among Patients with Type 2 Diabetic: Genetic Study in The Private Hospital in Yogyakarta. *J Farmasi Sains Komunitas JFSK*. 2022;19(2):53-61. DOI: [10.24071/jpsc.003902](https://doi.org/10.24071/jpsc.003902)

7. Liu X, Bragg F, Yang L, Kartsonaki C, Guo Y, Du H, et al. Smoking and smoking cessation in relation to risk of diabetes in Chinese men and women: a 9-year prospective study of 0.5 million people. *Lancet Public Health*. 2018;3(4):167–76. DOI: [10.1016/s2468-2667\(18\)30026-4](https://doi.org/10.1016/s2468-2667(18)30026-4); PMID: [29548855](https://pubmed.ncbi.nlm.nih.gov/29548855/)
8. Hong JW, Ku CR, Noh JH, Ko KS, Rhee BD, Kim DJ. Association between self-reported smoking and hemoglobin A1c in a Korean population without diabetes: The 2011–2012 Korean national health and nutrition examination survey. *PLoS One*. 2015;10(5):e0126746. DOI: [10.1371/journal.pone.0126746](https://doi.org/10.1371/journal.pone.0126746); PMID: [26011526](https://pubmed.ncbi.nlm.nih.gov/26011526/)
9. Vlassopoulos A, Lean MEJ, Combet E. Influence of Smoking and Diet on Glycated Haemoglobin and 'Pre-Diabetes' Categorisation: A Cross-Sectional Analysis. *BMC Public Health*. 2013;13:1013. DOI: [10.1186/1471-2458-13-1013](https://doi.org/10.1186/1471-2458-13-1013); PMID: [24499114](https://pubmed.ncbi.nlm.nih.gov/24499114/)
10. Kaiafa G, Veneti S, Polychronopoulos G, Pilalas D, Daios S, Kanellos I, et al. Is HbA1c an ideal biomarker of well-controlled diabetes? *Postgrad Med J*. 2021;97(1148):380–3. DOI: [10.1136/postgradmedj-2020-138756](https://doi.org/10.1136/postgradmedj-2020-138756); PMID: [32913038](https://pubmed.ncbi.nlm.nih.gov/32913038/)
11. Kaplan AK, Sezgin Y. Evaluation of the Relationship Between Smoking and Insulin Resistance: A Case-Control Study. *Cureus*. 2023;15(3):e36684. DOI: [10.7759/cureus.36684](https://doi.org/10.7759/cureus.36684); PMID: [36987444](https://pubmed.ncbi.nlm.nih.gov/36987444/)
12. Benowitz NL, St Helen G, Dempsey DA, Jacob 3<sup>rd</sup> P, Tyndale RF. Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. *Pharmacogenet Genomics*. 2016;26(7):340–50. DOI: [10.1097/fpc.0000000000000222](https://doi.org/10.1097/fpc.0000000000000222); PMID: [27035242](https://pubmed.ncbi.nlm.nih.gov/27035242/)
13. Patramurti C, Fenty F. Genetic Polymorphism Cytochrome P4502a6 Allel \*4 And \*9: Studi On Glycohemoglobine Level Among Javanese Indonesian Smokers. *Pharm Sci Res*. 2019;6(2):82–8. DOI: [10.7454/psr.v6i2.4488](https://doi.org/10.7454/psr.v6i2.4488)
14. Liu T, Xie C-B, Ma W-J, Chen W-Q. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. *Environ Mol Mutagen*. 2013;54(2):133–40. DOI: [10.1002/em.21751](https://doi.org/10.1002/em.21751); PMID: [23203414](https://pubmed.ncbi.nlm.nih.gov/23203414/)
15. Patramurti C, Nurrochmad A, Martono S, Science P, Mada G, Chemistry P. Polymorphism of Cytochrome P450 2A6 (CYP2A6\*1 and CYP2A6\*4) among Javanese Indonesian Smoker and Non Smoker. *Indones J Pharm*. 2015;26(1):11–9. DOI: [10.14499/indonesianjpharm26iss1pp11](https://doi.org/10.14499/indonesianjpharm26iss1pp11)
16. Patramurti C, Fenty F. Association of Smoking Behaviour and Glycohemoglobine Levels Among Adults Javanese Indonesian Smokers. *J Farmasi Sains Komunitas JFSK*. 2020;17(2):76–85. DOI: [10.24071/jpsc.002408](https://doi.org/10.24071/jpsc.002408)
17. Patramurti C, Virginia DM. Distribution of cytochrome P450\*4 (CYP2A6\*4) allele gene among Javanese Indonesian T2DM patients. *Pharmaciana*. 2021;11(1):25–38. DOI: [10.12928/pharmaciana.v11i1.18468](https://doi.org/10.12928/pharmaciana.v11i1.18468)
18. Aryanti GAKW, Priastana IKA. Modified Fagerstrom Tolerance Questionnaire (Adolescents) Indonesian Version: Validity and Reliability Study. *Indones J Health Res*. 2019;2(1):16–22. DOI: [10.32805/ijhr.2019.2.1.28](https://doi.org/10.32805/ijhr.2019.2.1.28)
19. Feng X, Qian Z, Zhang B, Guo E, Wang L, Liu P, et al. Number of Cigarettes Smoked Per Day, Smoking Index, and Intracranial Aneurysm Rupture: A Case-Control Study. *Front Neurol*. 2018;9:380. DOI: [10.3389/fneur.2018.00380](https://doi.org/10.3389/fneur.2018.00380); PMID: [29904368](https://pubmed.ncbi.nlm.nih.gov/29904368/)
20. Lin M, Chu M, Li X, Ma H, Fang Z, Mao L, et al. Factors influencing adolescent experimental and current smoking behaviors based on social cognitive theory: A cross-sectional study in Xiamen. *Front Public Health*. 2023;11:1093264. DOI: [10.3389/fpubh.2023.1093264](https://doi.org/10.3389/fpubh.2023.1093264); PMID: [37033036](https://pubmed.ncbi.nlm.nih.gov/37033036/)
21. Noubiap JJ, Nansseu JR, Endomba FT, Ngouo A, Nkeck JR, Nyaga UF, et al. Active smoking among people with diabetes mellitus or hypertension in Africa: a systematic review and meta-analysis. *Sci Rep*. 2019;9(1):588. DOI: [10.1038/s41598-018-37858-z](https://doi.org/10.1038/s41598-018-37858-z); PMID: [30679752](https://pubmed.ncbi.nlm.nih.gov/30679752/)
22. Akter S, Goto A, Mizoue T. Smoking and the risk of type 2 diabetes in Japan: A systematic review and meta-analysis. *J Epidemiol*. 2017;27(12):553–61. DOI: [10.1016/j.je.2016.12.017](https://doi.org/10.1016/j.je.2016.12.017); PMID: [28716381](https://pubmed.ncbi.nlm.nih.gov/28716381/)

23. Akkuzulu H, Aypak C, Özdemir A, Görpelioğlu S. Impact of smoking and nicotine addiction on HbA1c levels and diabetic microvascular complications. *Clin Diabetol*. 2020;9(2):112–7. DOI: [10.5603/DK.2020.0004](https://doi.org/10.5603/DK.2020.0004)
24. Maddatu J, Anderson-baucum E, Evans-molina C, Physiology I. Smoking and the Risk of Type 2 Diabetes. *Transl Res*. 2017;184:101–7. DOI: [10.1016/j.trsl.2017.02.004](https://doi.org/10.1016/j.trsl.2017.02.004); PMCID: [PMC5429867](https://pubmed.ncbi.nlm.nih.gov/28336465/); PMID: [28336465](https://pubmed.ncbi.nlm.nih.gov/28336465/)
25. Campagna D, Alamo A, Pino A Di, Russo C, Calogero AE, Purrello F, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. *Diabetol Metab Syndr*. 2019;11:85. DOI: [10.1186/s13098-019-0482-2](https://doi.org/10.1186/s13098-019-0482-2); PMCID: [PMC6813988](https://pubmed.ncbi.nlm.nih.gov/31666811/); PMID: [31666811](https://pubmed.ncbi.nlm.nih.gov/31666811/)
26. Yuan S, Larsson SC. A causal relationship between cigarette smoking and type 2 diabetes mellitus: A Mendelian randomization study. *Sci Rep*. 2019;9(1):19342. DOI: [10.1038/s41598-019-56014-9](https://doi.org/10.1038/s41598-019-56014-9); PMCID: [PMC6920406](https://pubmed.ncbi.nlm.nih.gov/31852999/); PMID: [31852999](https://pubmed.ncbi.nlm.nih.gov/31852999/)
27. Sliwińska-Mossoń M, Milnerowicz H. Influence of tobacco smoking on lipase activity in patients with pancreatitis. *Przegląd Lek*. 2005;62(10):1058–61. PMID: [16521953](https://pubmed.ncbi.nlm.nih.gov/16521953/)
28. Bajaj M. Nicotine and Insulin Resistance: When the Smoke Clears. *Diabetes*. 2012;61(12):3078–80. DOI: [10.2337/db12-1100](https://doi.org/10.2337/db12-1100); PMCID: [PMC3501863](https://pubmed.ncbi.nlm.nih.gov/23172960/); PMID: [23172960](https://pubmed.ncbi.nlm.nih.gov/23172960/)
29. Xie X, Liu Q, Wu J, Wakui M. Impact of cigarette smoking in type 2 diabetes development. *Acta Pharmacol Sin*. 2009;30(6):784–7. DOI: [10.1038/aps.2009.49](https://doi.org/10.1038/aps.2009.49); PMCID: [PMC4002374](https://pubmed.ncbi.nlm.nih.gov/19434055/); PMID: [19434055](https://pubmed.ncbi.nlm.nih.gov/19434055/)
30. Morimoto A, Tatsumi Y, Deura K, Mizuno S, Ohno Y, Watanabe S. Impact of cigarette smoking on impaired insulin secretion and insulin resistance in Japanese men: The Saku Study. *J Diabetes Investig*. 2013;4(3):274–80. DOI: [10.1111/jdi.12019](https://doi.org/10.1111/jdi.12019); PMCID: [PMC4015664](https://pubmed.ncbi.nlm.nih.gov/24843666/); PMID: [24843666](https://pubmed.ncbi.nlm.nih.gov/24843666/)
31. Somm E, Schwitzgebel VM, Vauthay DM, Camm EJ, Chen CY, Giacobino JP, et al. Prenatal nicotine exposure alters early pancreatic islet and adipose tissue development with consequences on the control of body weight and glucose metabolism later in life. *Endocrinology*. 2008;149(12):6289–99. DOI: [10.1210/en.2008-0361](https://doi.org/10.1210/en.2008-0361); PMID: [18687784](https://pubmed.ncbi.nlm.nih.gov/18687784/)
32. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomark Insights*. 2016;11:95-104. DOI: [10.4137/bmi.s38440](https://doi.org/10.4137/bmi.s38440); PMCID: [PMC4933534](https://pubmed.ncbi.nlm.nih.gov/27398023/); PMID: [27398023](https://pubmed.ncbi.nlm.nih.gov/27398023/)
33. Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. *Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015*. Jakarta: Pengurus Besar Perkumpulan Endokrinologi Indonesia; 2015. p. 78.
34. Choi DW, Jeon J, Lee SA, Han KT, Park EC, Jang SI. Association between smoking behavior patterns and glycosylated hemoglobin levels in a general population. *Int J Environ Res Public Health*. 2018;15(10):2260. DOI: [10.3390/ijerph15102260](https://doi.org/10.3390/ijerph15102260); PMCID: [PMC6210515](https://pubmed.ncbi.nlm.nih.gov/30332732/); PMID: [30332732](https://pubmed.ncbi.nlm.nih.gov/30332732/)
35. Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum? *Indian J Endocrinol Metab*. 2016;20(4):546-51. DOI: [10.4103/2230-8210.183480](https://doi.org/10.4103/2230-8210.183480); PMCID: [PMC4911847](https://pubmed.ncbi.nlm.nih.gov/27366724/); PMID: [27366724](https://pubmed.ncbi.nlm.nih.gov/27366724/)
36. Soewondo P, Ferrario A, Tahapary DL. Challenges in diabetes management in Indonesia: a literature review. *Global Health*. 2013;9:63. DOI: [10.1186/1744-8603-9-63](https://doi.org/10.1186/1744-8603-9-63); PMCID: [PMC3901560](https://pubmed.ncbi.nlm.nih.gov/24299164/); PMID: [24299164](https://pubmed.ncbi.nlm.nih.gov/24299164/)
37. Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. *Drug Metabol Drug Interact*. 2012;27(2):73–88. DOI: [10.1515/dmdi-2012-0001](https://doi.org/10.1515/dmdi-2012-0001); PMID: [22706231](https://pubmed.ncbi.nlm.nih.gov/22706231/)
38. Ismail L, Materwala H, Al Kaabi J. Association of risk factors with type 2 diabetes: A systematic review. *Comput Struct Biotechnol J*. 2021;19:1759-85. DOI: [10.1016/j.csbj.2021.03.003](https://doi.org/10.1016/j.csbj.2021.03.003); PMCID: [PMC8050730](https://pubmed.ncbi.nlm.nih.gov/33897980/); PMID: [33897980](https://pubmed.ncbi.nlm.nih.gov/33897980/)



39. Chenoweth MJ, O'Loughlin J, Sylvestre MP, Tyndale RF. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. *Pharmacogenet Genomics*. 2013;23(4):232–5. DOI: [10.1097/fpc.0b013e32835f834d](https://doi.org/10.1097/fpc.0b013e32835f834d); PMCID: [PMC3744214](https://pubmed.ncbi.nlm.nih.gov/23462429/); PMID: [23462429](https://pubmed.ncbi.nlm.nih.gov/23462429/)
40. O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshfedjian G, McMillan-Davey E, et al. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. *Tob Control*. 2004;13(4):422–8. DOI: [10.1136/tc.2003.007070](https://doi.org/10.1136/tc.2003.007070); PMCID: [PMC1747926](https://pubmed.ncbi.nlm.nih.gov/15564629/); PMID: [15564629](https://pubmed.ncbi.nlm.nih.gov/15564629/)
41. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. *Pharmacogenetics*. 2004;14(9):615–26. DOI: [10.1097/00008571-200409000-00006](https://doi.org/10.1097/00008571-200409000-00006); PMID: [15475735](https://pubmed.ncbi.nlm.nih.gov/15475735/)
42. Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, et al. In vivo Evaluation of Coumarin and Nicotine as Probe Drugs to Predict the Metabolic Capacity of CYP2A6 Due to Genetic Polymorphism in Thais. *Drug Metab Pharmacokinet*. 2006;21(6):475–84. DOI: [10.2133/dmpk.21.475](https://doi.org/10.2133/dmpk.21.475); PMID: [17220563](https://pubmed.ncbi.nlm.nih.gov/17220563/)
43. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during Ad libitum smoking. *Cancer Epidemiol Biomarkers Prev*. 2006;15(10):1812–9. DOI: [10.1158/1055-9965.epi-05-0723](https://doi.org/10.1158/1055-9965.epi-05-0723); PMID: [17035386](https://pubmed.ncbi.nlm.nih.gov/17035386/)
44. Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P, et al. Associations of CYP2A6 genotype with smoking behaviors in southern China. *Addiction*. 2011;106(5):985–94. DOI: [10.1111/j.1360-0443.2010.03353.x](https://doi.org/10.1111/j.1360-0443.2010.03353.x); PMCID: [PMC3074015](https://pubmed.ncbi.nlm.nih.gov/21205058/); PMID: [21205058](https://pubmed.ncbi.nlm.nih.gov/21205058/)
45. von Weymarn LB, Retzlaff C, Murphy SE. CYP2A6- and CYP2A13-Catalyzed Metabolism of the Nicotine. *J Pharmacol Exp Ther*. 2012;343(2):307–15. DOI: [10.1124/jpet.112.195255](https://doi.org/10.1124/jpet.112.195255); PMCID: [PMC3477218](https://pubmed.ncbi.nlm.nih.gov/22869927/); PMID: [22869927](https://pubmed.ncbi.nlm.nih.gov/22869927/)
46. Başpınar MM, Basat O. Does a High Pre-Treatment Nicotine Dependence Increase the Post-Cessation Diabetes Risk? *Turkish J Fam Med Prim Care*. 2021;15(2):244–50. DOI: [10.21763/tjfmpc.776077](https://doi.org/10.21763/tjfmpc.776077)
47. Yalcin E, de la Monte S. Tobacco nitrosamines as culprits in disease: mechanisms reviewed. *J Physiol Biochem*. 2017;72(1):107–20. DOI: [10.1007/s13105-016-0465-9](https://doi.org/10.1007/s13105-016-0465-9); PMCID: [PMC4868960](https://pubmed.ncbi.nlm.nih.gov/26767836/); PMID: [26767836](https://pubmed.ncbi.nlm.nih.gov/26767836/)
48. Yuan J, Nelson HH, Carmella SG, Wang R, Kuriger-laber J, Jin A, et al. CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study. *Carcinogenesis*. 2017;38(4):411–8. DOI: [10.1093/carcin/bgx012](https://doi.org/10.1093/carcin/bgx012); PMCID: [PMC6248819](https://pubmed.ncbi.nlm.nih.gov/28182203/); PMID: [28182203](https://pubmed.ncbi.nlm.nih.gov/28182203/)
49. Liu Y, Xu Y, Li F, Chen H, Guo S. CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. *Tumour Biol*. 2013;34(5):2651–7. DOI: [10.1007/s13277-013-0815-y](https://doi.org/10.1007/s13277-013-0815-y); PMID: [23649654](https://pubmed.ncbi.nlm.nih.gov/23649654/)
50. Bergman BC, Perreault L, Hunerdosse D, Kerege A, Playdon M, Samek AM, et al. Novel and Reversible Mechanisms of Smoking-Induced Insulin Resistance in Humans. *Diabetes*. 2012;61(12):3156–66. DOI: [10.2337/db12-0418](https://doi.org/10.2337/db12-0418); PMCID: [PMC3501865](https://pubmed.ncbi.nlm.nih.gov/22966072/); PMID: [22966072](https://pubmed.ncbi.nlm.nih.gov/22966072/)
51. Cho NH, Chan JCN, Jang HC, Lim S, Kim HL, Choi SH. Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study. *J Clin Endocrinol*. 2009;71(5):679–85. DOI: [10.1111/j.1365-2265.2009.03586.x](https://doi.org/10.1111/j.1365-2265.2009.03586.x); PMID: [19508609](https://pubmed.ncbi.nlm.nih.gov/19508609/)
52. Sobue S, Sekiguchi K, Kikkawa H, Akasaki M, Irie S. Comparison of nicotine pharmacokinetics in healthy Japanese male smokers following application of the transdermal nicotine patch and cigarette smoking. *Biol Pharm Bull*. 2006;29(5):1068–73. DOI: [10.1248/bpb.29.1068](https://doi.org/10.1248/bpb.29.1068); PMID: [16651750](https://pubmed.ncbi.nlm.nih.gov/16651750/)
53. Nilsson PM, Gudbjörnsdottir S, Eliasson B, Cederholm J, Steering Committee of the Swedish National Diabetes Register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes—data from the

- National Diabetes Register in Sweden. *Diabetes Metab.* 2004;30(3):261–8. DOI: [10.1016/s1262-3636\(07\)70117-9](https://doi.org/10.1016/s1262-3636(07)70117-9); PMID: 15223978
54. Minematsu N, Nakamura H, Furuuchi M, Nakajima T, Takahashi S, Tateno H, et al. Limitation of cigarette consumption by CYP2A6\*4, \*7 and \*9 polymorphisms. *Eur Respir J.* 2006;27(2):289–92. DOI: [10.1183/09031936.06.00056305](https://doi.org/10.1183/09031936.06.00056305); PMID: 16452582
55. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. *Carcinogenesis.* 2004;25(12):2451–8. DOI: [10.1093/carcin/bgh258](https://doi.org/10.1093/carcin/bgh258); PMID: 15308589
56. Ando M, Hamajima N, Ariyoshi N, Kamataki T, Matsuo K. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. *J Epidemiol.* 2003;13(3):176–81. DOI: [10.2188/jea.13.176](https://doi.org/10.2188/jea.13.176); PMCID: [PMC9634051](https://pubmed.ncbi.nlm.nih.gov/PMC9634051/); PMID: 12749606
57. Hermansach R, Bachtiar A. An Overview of Active Smokers' Perceptions of the Policy of Inclusion of Pictorial Warnings of the Dangers of Smoking Oncigarette Packs in Pondok Gede Sub-District, Bekasi City. *J Indones Health Policy Adm.* 2021;6(3):192-8. DOI: [10.7454/ihpa.v6i3.4466](https://doi.org/10.7454/ihpa.v6i3.4466)
58. Tan YL, Dorotheo U. *The Tobacco Control Atlas ASEAN Region, Fourth Edition.* Bangkok: Southeast Asia Tobacco Control Alliance (SEATCA); 2018. p. 105.